Pushkal P. Garg's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 767 Common Stock done at an average price of $323.8 . Disclosure was reported to the exchange on March 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 323.84 per share. | 04 Mar 2026 | 767 | 21,577 (0%) | 0% | 323.8 | 248,385 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 323.55 per share. | 04 Mar 2026 | 740 | 19,703 (0%) | 0% | 323.6 | 239,427 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 322.33 per share. | 04 Mar 2026 | 654 | 20,443 (0%) | 0% | 322.3 | 210,804 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 324.59 per share. | 04 Mar 2026 | 510 | 19,193 (0%) | 0% | 324.6 | 165,541 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 326.08 per share. | 04 Mar 2026 | 500 | 18,693 (0%) | 0% | 326.1 | 163,040 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 323.01 per share. | 04 Mar 2026 | 350 | 22,344 (0%) | 0% | 323.0 | 113,054 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 321.82 per share. | 04 Mar 2026 | 289 | 22,694 (0%) | 0% | 321.8 | 93,006 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 324.88 per share. | 04 Mar 2026 | 272 | 21,305 (0%) | 0% | 324.9 | 88,367 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 320.81 per share. | 04 Mar 2026 | 215 | 22,983 (0%) | 0% | 320.8 | 68,974 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 325.67 per share. | 04 Mar 2026 | 208 | 21,097 (0%) | 0% | 325.7 | 67,739 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 319.03 per share. | 04 Mar 2026 | 106 | 23,300 (0%) | 0% | 319.0 | 33,817 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 320.01 per share. | 04 Mar 2026 | 102 | 23,198 (0%) | 0% | 320.0 | 32,641 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 10,480 | 10,480 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 4,769 | 26,898 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 320.48 per share. | 02 Mar 2026 | 640 | 23,869 (0%) | 0% | 320.5 | 205,107 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 321.50 per share. | 02 Mar 2026 | 463 | 23,406 (0%) | 0% | 321.5 | 148,855 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 326.81 per share. | 02 Mar 2026 | 421 | 26,053 (0%) | 0% | 326.8 | 137,587 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 316.74 per share. | 02 Mar 2026 | 355 | 24,826 (0%) | 0% | 316.7 | 112,443 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 327.67 per share. | 02 Mar 2026 | 353 | 25,700 (0%) | 0% | 327.7 | 115,668 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 319.06 per share. | 02 Mar 2026 | 317 | 24,509 (0%) | 0% | 319.1 | 101,142 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 325.63 per share. | 02 Mar 2026 | 277 | 26,474 (0%) | 0% | 325.6 | 90,200 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 329.71 per share. | 02 Mar 2026 | 182 | 25,411 (0%) | 0% | 329.7 | 60,007 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 328.71 per share. | 02 Mar 2026 | 107 | 25,593 (0%) | 0% | 328.7 | 35,172 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 331.93 per share. | 02 Mar 2026 | 101 | 25,223 (0%) | 0% | 331.9 | 33,525 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 324.65 per share. | 02 Mar 2026 | 97 | 26,751 (0%) | 0% | 324.6 | 31,491 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 330.85 per share. | 02 Mar 2026 | 87 | 25,324 (0%) | 0% | 330.9 | 28,784 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 323.62 per share. | 02 Mar 2026 | 50 | 26,848 (0%) | 0% | 323.6 | 16,181 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 332.64 per share. | 02 Mar 2026 | 42 | 25,181 (0%) | 0% | 332.6 | 13,971 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 330.73 per share. | 27 Feb 2026 | 2,259 | 24,370 (0%) | 0% | 330.7 | 747,119 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2026 | 1,908 | 0 | - | - | Restricted Stock Units | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2026 | 1,908 | 26,756 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 331.49 per share. | 27 Feb 2026 | 1,159 | 23,211 (0%) | 0% | 331.5 | 384,197 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 332.48 per share. | 27 Feb 2026 | 942 | 22,269 (0%) | 0% | 332.5 | 313,196 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 334.39 per share. | 27 Feb 2026 | 140 | 22,129 (0%) | 0% | 334.4 | 46,815 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 328.92 per share. | 27 Feb 2026 | 127 | 26,629 (0%) | 0% | 328.9 | 41,773 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 4,579 | 27,090 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 310.08 per share. | 12 Feb 2026 | 2,242 | 24,848 (0%) | 0% | 310.1 | 695,201 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2026 | 3,800 | 24,021 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 365.56 per share. | 11 Jan 2026 | 220 | 22,803 (0%) | 0% | 365.6 | 80,423 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 364.83 per share. | 11 Jan 2026 | 199 | 23,023 (0%) | 0% | 364.8 | 72,601 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 360.22 per share. | 11 Jan 2026 | 155 | 23,440 (0%) | 0% | 360.2 | 55,834 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 358.18 per share. | 11 Jan 2026 | 123 | 23,680 (0%) | 0% | 358.2 | 44,056 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 361.45 per share. | 11 Jan 2026 | 98 | 23,342 (0%) | 0% | 361.4 | 35,422 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 357.17 per share. | 11 Jan 2026 | 96 | 23,803 (0%) | 0% | 357.2 | 34,288 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 368.62 per share. | 11 Jan 2026 | 92 | 22,620 (0%) | 0% | 368.6 | 33,913 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 359.14 per share. | 11 Jan 2026 | 85 | 23,595 (0%) | 0% | 359.1 | 30,527 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 362.38 per share. | 11 Jan 2026 | 73 | 23,269 (0%) | 0% | 362.4 | 26,454 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 366.42 per share. | 11 Jan 2026 | 50 | 22,753 (0%) | 0% | 366.4 | 18,321 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 363.55 per share. | 11 Jan 2026 | 47 | 23,222 (0%) | 0% | 363.6 | 17,087 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 355.17 per share. | 11 Jan 2026 | 42 | 23,940 (0%) | 0% | 355.2 | 14,917 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 356.10 per share. | 11 Jan 2026 | 41 | 23,899 (0%) | 0% | 356.1 | 14,600 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 367.39 per share. | 11 Jan 2026 | 41 | 22,712 (0%) | 0% | 367.4 | 15,063 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 369.48 per share. | 11 Jan 2026 | 40 | 22,580 (0%) | 0% | 369.5 | 14,779 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 353.95 per share. | 11 Jan 2026 | 39 | 23,982 (0%) | 0% | 353.9 | 13,804 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 375.63 per share. | 11 Jan 2026 | 19 | 22,526 (0%) | 0% | 375.6 | 7,137 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 370.89 per share. | 11 Jan 2026 | 18 | 22,562 (0%) | 0% | 370.9 | 6,676 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 377.80 per share. | 11 Jan 2026 | 15 | 22,511 (0%) | 0% | 377.8 | 5,667 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 374.43 per share. | 11 Jan 2026 | 14 | 22,545 (0%) | 0% | 374.4 | 5,242 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 372.33 per share. | 11 Jan 2026 | 3 | 22,559 (0%) | 0% | 372.3 | 1,117 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 3,108 | 23,329 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 2,851 | 26,180 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 451.76 per share. | 01 Oct 2025 | 898 | 20,853 (0%) | 0% | 451.8 | 405,680 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 450.63 per share. | 01 Oct 2025 | 810 | 21,751 (0%) | 0% | 450.6 | 365,010 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 449.99 per share. | 01 Oct 2025 | 682 | 22,561 (0%) | 0% | 450.0 | 306,893 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 452.69 per share. | 01 Oct 2025 | 668 | 24,039 (0%) | 0% | 452.7 | 302,397 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 450.81 per share. | 01 Oct 2025 | 541 | 25,039 (0%) | 0% | 450.8 | 243,888 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 453.51 per share. | 01 Oct 2025 | 417 | 20,436 (0%) | 0% | 453.5 | 189,114 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 451.86 per share. | 01 Oct 2025 | 332 | 24,707 (0%) | 0% | 451.9 | 150,018 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 453.77 per share. | 01 Oct 2025 | 329 | 23,710 (0%) | 0% | 453.8 | 149,290 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 449.79 per share. | 01 Oct 2025 | 249 | 25,580 (0%) | 0% | 449.8 | 111,998 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 454.84 per share. | 01 Oct 2025 | 244 | 23,466 (0%) | 0% | 454.8 | 110,981 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 454.37 per share. | 01 Oct 2025 | 215 | 20,221 (0%) | 0% | 454.4 | 97,690 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 448.77 per share. | 01 Oct 2025 | 180 | 25,829 (0%) | 0% | 448.8 | 80,779 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 457.43 per share. | 01 Oct 2025 | 147 | 23,246 (0%) | 0% | 457.4 | 67,242 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 446.53 per share. | 01 Oct 2025 | 115 | 26,065 (0%) | 0% | 446.5 | 51,351 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 455.82 per share. | 01 Oct 2025 | 73 | 23,393 (0%) | 0% | 455.8 | 33,275 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 447.93 per share. | 01 Oct 2025 | 56 | 26,009 (0%) | 0% | 447.9 | 25,084 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 457.67 per share. | 01 Oct 2025 | 3 | 23,243 (0%) | 0% | 457.7 | 1,373 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 2,851 | 23,072 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 454.04 per share. | 15 Aug 2025 | 543 | 21,929 (0%) | 0% | 454.0 | 246,544 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 457.26 per share. | 15 Aug 2025 | 338 | 21,062 (0%) | 0% | 457.3 | 154,554 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 452.96 per share. | 15 Aug 2025 | 329 | 22,472 (0%) | 0% | 453.0 | 149,024 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 461.01 per share. | 15 Aug 2025 | 305 | 20,266 (0%) | 0% | 461.0 | 140,608 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 455.41 per share. | 15 Aug 2025 | 276 | 21,400 (0%) | 0% | 455.4 | 125,693 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 459.59 per share. | 15 Aug 2025 | 260 | 20,571 (0%) | 0% | 459.6 | 119,493 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 454.84 per share. | 15 Aug 2025 | 241 | 21,688 (0%) | 0% | 454.8 | 109,616 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 458.27 per share. | 15 Aug 2025 | 231 | 20,831 (0%) | 0% | 458.3 | 105,860 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 451.99 per share. | 15 Aug 2025 | 103 | 22,801 (0%) | 0% | 452.0 | 46,555 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 449.92 per share. | 15 Aug 2025 | 90 | 22,943 (0%) | 0% | 449.9 | 40,493 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 461.73 per share. | 15 Aug 2025 | 45 | 20,221 (0%) | 0% | 461.7 | 20,778 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 450.92 per share. | 15 Aug 2025 | 39 | 22,904 (0%) | 0% | 450.9 | 17,586 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 447.97 per share. | 15 Aug 2025 | 39 | 23,033 (0%) | 0% | 448.0 | 17,471 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 455.83 per share. | 15 Aug 2025 | 12 | 21,676 (0%) | 0% | 455.8 | 5,470 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 300.00 per share. | 21 Mar 2025 | 5,445 | 20,221 (0%) | 0% | 300 | 1,633,500 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.22 per share. | 21 Mar 2025 | 5,445 | 25,666 (0%) | 0% | 42.2 | 229,888 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2025 | 5,445 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 285.00 per share. | 21 Mar 2025 | 4,321 | 20,221 (0%) | 0% | 285 | 1,231,485 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 14,137 | 27,099 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 7,819 | 7,819 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 243.13 per share. | 03 Mar 2025 | 583 | 25,740 (0%) | 0% | 243.1 | 141,745 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 240.92 per share. | 03 Mar 2025 | 343 | 24,860 (0%) | 0% | 240.9 | 82,636 | Common Stock |